Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRF with Hexaminolevulinate for Bladder Cancer Detection
NCT03058705Completed
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hexaminolevulinate in bladder cancer. Primary endpoint: Minimal Dwell Time Needed for Adequate Detection at Day 1. Started Nov 2017; status: completed.
02
Drugs
hexaminolevulinate
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03058705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058705.